All In Biotech

BLA 021629 · Sanofi Aventis US

Apidra Solostar

Insulin Glulisine Recombinant · Subcutaneous, Intravenous, Subcutaneous · Insulin Analog

Novel

Last checked: Nov 20, 2026Latest source record: Nov 30, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Apr 16, 2004

Approved uses

3

Original approval plus efficacy supplements

Registered trials

98

28 Phase 3, 0 recruiting

FAERS reports

10,207

7,737 serious, 819 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 25, 2025.

APIDRA is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. APIDRA is a rapid-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ( 1 )

Mechanism: Regulation of glucose metabolism is the primary activity of insulins and insulin analogs, including insulin glulisine. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis and enhance protein synthesis.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • APIDRA SOLOSTAR · INSULIN GLULISINE RECOMBINANT 300 UNITS/3ML · INJECTABLE, SUBCUTANEOUS · Prescription
  • APIDRA · INSULIN GLULISINE RECOMBINANT 1000 UNITS/10ML (100 UNITS/ML) · INJECTABLE, INTRAVENOUS, SUBCUTANEOUS · Prescription
  • APIDRA · INSULIN GLULISINE RECOMBINANT 300 UNITS/3ML (100 UNITS/ML) · INJECTABLE, INTRAVENOUS, SUBCUTANEOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Insulin Glulisine Recombinant" as an intervention, any sponsor and status, largest first.

All 98 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood glucose increased1,577
  • hypoglycaemia785
  • hyperglycaemia655
  • drug ineffective582
  • blood glucose decreased455
  • dizziness407
  • malaise398
  • dyspnoea393
  • nausea380
  • vomiting348
  • acute kidney injury310
  • fatigue310

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20059
200673
2007187
2008119
2009197
2010291
2011480
2012513
2013578
2014867
20151,076
2016615
2017613
2018968
2019869
2020576
2021428
2022470
2023384
2024345
2025295
2026254

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Apidra (Insulin Glulisine)

2024 spending

$735K

Beneficiaries

667

2,245 claims

Per beneficiary

$1,102

$8.00 per unit

View as table
YearSpending
2020$4,528,780
2021$3,769,932
2022$3,030,250
2023$2,769,322
2024$735,198

Part D: Apidra Solostar (Insulin Glulisine)

2024 spending

$2.3M

Beneficiaries

2,523

8,018 claims

Per beneficiary

$910

$10.33 per unit

View as table
YearSpending
2020$12,268,555
2021$10,338,191
2022$9,202,504
2023$8,643,475
2024$2,296,756

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Sanofi · Also marketed as Apidra

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.